Market Research Reports

Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

98pages
Published Date: 2013-10-21
 

Description


The global erectile dysfunction drugs market is led by North America and the region will continue to maintain its leading position during the forecast period owing to the presence of major erectile dysfunction drugs such as Viagra and Cialis. 

The erectile dysfunction drugs market report offers an insightful and in-depth assessment of the structure and various elements of the erectile dysfunction drugs market. The report provides a comprehensive introduction of the market, together with industry history, product and geographical classification, and value chain analysis. Key aspects such as production, supply and consumption analysis, price cost and profit evaluation, growth drivers and inhibitors, and details regarding imports and exports have been provided in the erectile dysfunction drugs report with critical insights and recommendations.

Overview of the global erectile dysfunction drugs market

The worldwide erectile dysfunction drugs market is primarily driven by growing geriatric population, rise in incidences of numerous diseases, preference towards sedentary lifestyle, and increasing focus on patient education and awareness. In addition to this, the growing impact of generics, ongoing clinical trials and tests for erectile dysfunction drugs, blockbuster patent expirations, innovative drug delivery techniques, and new molecule combinations are some of the areas that hold immense growth opportunities for the erectile dysfunction drugs market.

On the other hand, diminishing insurance coverage for the treatment of erectile dysfunction, increasing threat from counterfeit drugs, weak pipeline development, and increasing prevalence of sexually transmitted diseases (STDs) among users of erectile dysfunction drugs are expected to hamper the growth of the market. Moreover, the expectant patent expiration of Eli Lilly & Co.’s Cialis and Bayer AG’s Levitra, and that of industry leader Pfizer’s Viagra outside the U.S. in 2013 is estimated to greatly impact the erectile dysfunction drugs market. 

Geographically, North America led the global erectile dysfunction drugs market and was estimated to be worth US$2,098.4 million in 2012. While patent expiration of blockbuster erectile dysfunction drugs is expected to restrain the growth of the erectile dysfunction drugs market in developed regions, their increasing adoption in emerging economies is expected to drive the global erectile dysfunction drugs market.

Companies mentioned in the research report

The research report on erectile dysfunction drugs market profiles the leading players operating in the market. Highlighting individual strengths, weakness, opportunities, and threats, the report offers a detailed analysis on the various participants in the erectile dysfunction drugs market. It also tracks and anticipates numerous trends and developments in the competitive landscape and offers critical and strategic recommendations based on data provided by authentic sources within the erectile dysfunction drugs market. The companies mentioned in the erectile dysfunction drugs market report are Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Vivus, Inc., Eli Lilly And Company, Apricus Biosciences, Inc., Dong-A Pharmaceutical Co. Ltd., Pfizer, Inc., S.K. Chemicals Co. Ltd., and Bayer AG.

Among these, Viagra by Pfizer, Inc. dominated the erectile dysfunction drugs market in 2012, followed by Eli Lilly & Co.’s Cialis and Bayer AG’s Levitra.

Major geographies analyzed under this research report are: 
  • EMEA
  • North America 
  • Asia-Pacific 
  • Rest of the World 
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Contents


Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Erectile Dysfunction
3.2 Current Market Trends and Future Outlook
      3.2.1 Impact of Generics
      3.2.2 Key Patent Expirations
      3.2.3 Ongoing Clinical Trials in the U.S. for ED Treatment (Phase III)
3.3 Types of Treatments for ED
      3.3.1 Phosphodiesterase Type 5 Inhibitors (PDE 5 Inhibitors)
      3.3.2 Localized Therapy
      3.3.3 Testosterone Replacement Therapy
      3.3.4 Vacuum Constriction Devices
      3.3.5 Surgery (Penile Implants and Vascular Surgery)
      3.3.6 Alternative Medicines (Yohimbine and Other Herb and Dietary Supplements)
3.4 Market Drivers
      3.4.1 Increase in Elderly Population
      3.4.2 Increasing Global Incidence of Various Diseases and Growing Preference Towards Sedentary Lifestyle
      3.4.3 Increase in Awareness and Patient Education
3.5 Market Restraints
      3.5.1 Prevalence of Sexually Transmitted Diseases with ED Drug Users
      3.5.2 Narrowing of Insurance Coverage for Erectile Dysfunction Treatment
      3.5.3 Growing Threat from Counterfeit Drugs
3.6 Market Opportunities
      3.6.1 Novel Molecule Combinations and Drug Delivery Techniques are Expected to Become a Rising Opportunity
      3.6.2 Generics - A Growing Global Opportunity
3.7 Porter’s Five Forces Analysis: Global Erectile Dysfunction Drugs Market
      3.7.1 Bargaining Power of Suppliers
      3.7.2 Bargaining Power of Buyers
      3.7.3 Threat of Substitutes
      3.7.4 Threat of New Entrants
      3.7.5 Competitive Rivalry
3.8 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)

Chapter 4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million)
4.1 Market Overview
      4.1.1 Mechanism of Action
      4.1.2 Characteristics of Major Phosphodiesterase Type 5 Inhibitors
4.2 Viagra (Sildenafil Citrate)
      4.2.1 Introduction
      4.2.2 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.2.3 Patent Expiration and Regulatory Scenario
              4.2.3.1 The U.S. Market
              4.2.3.2 International Market
      4.2.4 Past & Current Market Scenario
      4.2.5 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.2.6 Future Market Scenario
      4.2.7 Global Viagra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.3 Cialis (Tadalafil)
      4.3.1 Introduction
      4.3.2 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.3.3 Patent and Regulatory Scenario
      4.3.4 Current Market Scenario and Patent Expiry Effect
      4.3.5 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.3.6 Future Market Scenario
      4.3.7 Global Cialis Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.4 Levitra/Staxyn (Vardenafil)
      4.4.1 Introduction
      4.4.2 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.4.3 Patent and Regulatory Scenario
      4.4.4 Current and Future Market Scenario
      4.4.5 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.4.6 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.5 Stendra/Spedra (Avanafil)
      4.5.1 Introduction
      4.5.2 Future Market Scenario
      4.5.3 Global Stendra/Spedra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.6 Zydena (Udenafil)
      4.6.1 Introduction
      4.6.2 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.6.3 Current Market Scenario
      4.6.4 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.6.5 Future Market Scenario
      4.6.6 Global Zydena Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.7 MUSE (Medicated Urethral System for Erection)
      4.7.1 Patent and Regulatory Scenario
4.8 Mvix (Mirodenafil)
4.9 Helleva (Lodenafil Carbonate)

Chapter 5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis
5.1 Overview
5.2 Vitaros (Alprostadil)
      5.2.1 Global Vitaros Market for Erectile Dysfunction Treatment, 2014 – 2019 (USD Million)
5.3 Uprima (Apomorphine)
5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy)
      5.4.1 Topiglan
      5.4.2 Melanocortin Activators
      5.4.3 Gene Therapy

Chapter 6 Global Erectile Dysfunction Drugs Market, By Geography
6.1 Overview
      6.1.1 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2010 – 2019 (USD Million)
      6.1.2 Comparative Analysis: Global Erectile Dysfunction Drugs Market, By Geography, 2012 & 2019 (Value %)
6.2 North America
      6.2.1 North America Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.2.2 North America Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
6.3 Europe
      6.3.1 Europe Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.3.2 Europe Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
6.4 Asia-Pacific
      6.4.1 Asia-Pacific Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.4.2 Asia-Pacific Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
6.5 Rest of the World (Row)
      6.5.1 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.5.2 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2015 – 2019 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Erectile Dysfunction Drugs Market, 2012 (%)
      7.1.1 Methodology
      7.1.2 Analysis

Chapter 8 Recommendations
8.1 Novel Drug Formulations and Genericization owing to Patent Expiration of well recognized ED Drugs
8.2 Mergers and Acquisitions to Strengthen Market Presence
8.3 Cost Containment Measures

Chapter 9 Company Profiles
9.1 Apricus Biosciences, Inc.
      9.1.1 Company Overview
      9.1.2 Business Strategies
      9.1.3 Financial Overview
      9.1.4 Product Portfolio
      9.1.5 Recent Developments
9.2 Bayer AG
      9.2.1 Company Overview
      9.2.2 Business Strategies
      9.2.3 Financial Overview
      9.2.4 Product Portfolio
      9.2.5 Recent Developments
9.3 Cristalia Produtos Quimicos Farmaceuticos Ltda.
      9.3.1 Company Overview
      9.3.2 Business Strategies
      9.3.3 Product Portfolio
      9.3.4 Recent Developments
9.4 Dong-A Pharmaceutical Co. Ltd.
      9.4.1 Company Overview
      9.4.2 Business Strategies
      9.4.3 Financial Overview
      9.4.4 Product Portfolio
      9.4.5 Recent Developments
9.5 Eli Lilly And Company
      9.5.1 Company Overview
      9.5.2 Business Strategies
      9.5.3 Financial Overview
      9.5.4 Product Portfolio
      9.5.5 Recent Developments
9.6 Meda Pharmaceuticals, Inc.
      9.6.1 Company Overview
      9.6.2 Business Strategies
      9.6.3 Product Portfolio
      9.6.4 Recent Developments
9.7 Pfizer, Inc.
      9.7.1 Company Overview
      9.7.2 Business Strategies
      9.7.3 Financial Overview
      9.7.4 Product Portfolio
      9.7.5 Recent Developments
9.8 S.K. Chemicals Co. Ltd.
      9.8.1 Company Overview
      9.8.2 Business Strategies
      9.8.3 Financial Overview
      9.8.4 Product Portfolio
      9.8.5 Recent Developments
9.9 Vivus, Inc.
      9.9.1 Company Overview
      9.9.2 Business Strategies
      9.9.3 Financial Overview
      9.9.4 Product Portfolio
      9.9.5 Recent Developments

List of Figures

FIG. 1 Erectile Dysfunction Drugs Market Segmentation
FIG. 2 Global Erectile Dysfunction Drugs Market Revenue, 2010 - 2019 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Erectile Dysfunction Drugs Market
FIG. 4 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)
FIG. 5 PPDE 5 Inhibitors: Mechanism of Action
FIG. 6 Global Viagra Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 7 Global Viagra Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 8 Global Viagra Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 9 Global Cialis Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 10 Global Cialis Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 11 Global Cialis Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 12 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 13 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 14 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 15 Global Stendra/Spedra Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 16 Global Zydena Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 17 Global Zydena Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 18 Global Zydena Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 19 Global Vitaros Market For Erectile Dysfunction Treatment, 2014 – 2019 (USD Million)
FIG. 20 Comparative Analysis: Global Erectile Dysfunction Drugs Market, By Geography, 2012 & 2019 (Value %)
FIG. 21 North America Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 22 North America Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
FIG. 23 Europe Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 24 Europe Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
FIG. 25 Asia-Pacific Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 26 Asia-Pacific Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
FIG. 27 Rest Of The World (Row) Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 28 Rest Of The World (Row) Erectile Dysfunction Drugs Market, 2015 – 2019 (USD Million)
FIG. 29 Market Share By Key Players: Branded Formulations For Erectile Dysfunction Treatment, 2012 (%)
FIG. 30 Apricus Biosciences, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 31 Bayer AG: Annual Revenue, 2010 – 2012 (USD Million) (1 Euro = 1.35 USD)
FIG. 32 Dong-A Pharmaceutical Co. Ltd.: Annual Revenue, 2010 – 2012 (USD Million) (1 KRW = 0.0093 USD)
FIG. 33 Eli Lilly & Co.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 34 Pfizer, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 35 S. K. Chemicals Co. Ltd.: Annual Revenue, 2010 – 2012 (USD Million) (1 KRW = 0.0093 USD)

List of Tables

TABLE 1 Market Snapshot: Global Erectile Dysfunction Drugs Market
TABLE 2 Causes Of Erectile Dysfunction
TABLE 3 Ongoing Clinical Trials In The U.S. For ED Treatment (Phase III)
TABLE 4 Causes Of ED: Classes Of Drugs Used To Treat Chronic Diseases
TABLE 5 Global Erectile Dysfunction Drugs, 2010 – 2014 (USD Million)
TABLE 6 Global Erectile Dysfunction Drugs, 2015 – 2019 (USD Million)
TABLE 7 Characteristics Of PDE 5 Inhibitor Class Of Erectile Dysfunction Drugs
TABLE 8 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2010 – 2014 (USD Million)
TABLE 9 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2015 – 2019 (USD Million)

Enquiry Before Buying


Free Market Analysis



Erectile dysfunction (ED) is the inability to achieve or maintain satisfactory erection of penis during sexual intercourse. It is usually an age related condition but can also be triggered by psychological factors. It may occur due to various reasons such as smoking, sedentary lifestyle and administration of certain drugs such as antidepressants, psychotropic drugs, antihypertensive and recreational drugs. Presently, oral phosphodiesterase type 5 inhibitors (PDE 5) commonly form the first line of treatment prescribed by doctors for ED. These include drugs namely, Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil) and Zydena (udenafil). The demand for erectile dysfunction drugs is high and is continuously rising as it caters to the needs of the growing elderly population and the high incidence rates of chronic disorders comprising hypertension, renal diseases and diabetes, neurological disorders and hormonal insufficiencies. 

Erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013. In addition, Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG are also scheduled to lose their patent exclusivities during the forecast period. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. Moreover, low success rate of novel drug formulations owing to weak pipeline development will also account for the downturn of the overall erectile dysfunction drugs market.

Pfizer’s Viagra was the largest revenue generator in 2012, in the total market, owing to its foremost presence in the pharmaceutical market for erectile dysfunction treatment. Viagra has maintained its blockbuster status till date, recording billion dollar sales every year for Pfizer, Inc. The primary competitors on the market for Viagra are Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG. 

Geographically, North America dominated the global erectile dysfunction drugs market and is expected to continue to lead in terms of revenue generation throughout the forecast period. North America is considered as the most lucrative market for erectile dysfunction drugs owing to the presence of blockbuster drugs Viagra and Cialis in the U.S. market through 2019. The North American market for erectile dysfunction drugs was valued at USD 2,098.4 million in the year 2012. However, loss of patent exclusivities for Cialis (tadalafil) and Levitra/Staxyn (vardenafil) within the forecast period are expected to hamper market growth, though to a lesser extent. Factors such as increased market consolidation (due to influx of generics and weak pipeline development), cost containment measures coupled with introduction of cheaper products will result in rapid adoption of these drugs in the emerging markets. The leading players in the market for branded erectile dysfunction drugs are Pfizer, Inc., Eli Lilly & Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd and Vivus, Inc.

global-erectile-dysfunction-drugs-market-revenue-2010-2019
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research